GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CalciMedica Inc (NAS:CALC) » Definitions » Return-on-Tangible-Asset

CalciMedica (CalciMedica) Return-on-Tangible-Asset : 2.65% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is CalciMedica Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. CalciMedica's annualized Net Income for the quarter that ended in Mar. 2024 was $0.52 Mil. CalciMedica's average total tangible assets for the quarter that ended in Mar. 2024 was $19.66 Mil. Therefore, CalciMedica's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was 2.65%.

The historical rank and industry rank for CalciMedica's Return-on-Tangible-Asset or its related term are showing as below:

CALC' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -442.35   Med: -84.3   Max: -21.6
Current: -67.86

During the past 6 years, CalciMedica's highest Return-on-Tangible-Asset was -21.60%. The lowest was -442.35%. And the median was -84.30%.

CALC's Return-on-Tangible-Asset is ranked worse than
67.64% of 1548 companies
in the Biotechnology industry
Industry Median: -40.065 vs CALC: -67.86

CalciMedica Return-on-Tangible-Asset Historical Data

The historical data trend for CalciMedica's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CalciMedica Return-on-Tangible-Asset Chart

CalciMedica Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial -126.68 -38.65 -41.92 -21.60 -442.35

CalciMedica Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -405.87 -91.84 -102.39 -118.33 2.65

Competitive Comparison of CalciMedica's Return-on-Tangible-Asset

For the Biotechnology subindustry, CalciMedica's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CalciMedica's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CalciMedica's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where CalciMedica's Return-on-Tangible-Asset falls into.



CalciMedica Return-on-Tangible-Asset Calculation

CalciMedica's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-34.357/( (3.349+12.185)/ 2 )
=-34.357/7.767
=-442.35 %

CalciMedica's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=0.52/( (12.185+27.134)/ 2 )
=0.52/19.6595
=2.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


CalciMedica  (NAS:CALC) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


CalciMedica Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of CalciMedica's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


CalciMedica (CalciMedica) Business Description

Traded in Other Exchanges
N/A
Address
274 Redwood Shores Parkway, P.O. Box 144, Redwood City, CA, USA, 94065
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.
Executives
Robert N Wilson director C/O JOHNSON & JOHNSON, ONE JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
A. Rachel Leheny director, 10 percent owner, officer: Chief Executive Officer C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Eric W Roberts director, 10 percent owner, officer: Chief Business Officer VALENCE LIFE SCIENCES LLC, 500 PARK AVENUE 9TH FLOOR, NEW YORK NY 10022
Sudarshan Hebbar officer: Chief Medical Officer C/O CALCIMEDICA, INC., 505 COAST BOULEVARD SOUTH, LA JOLLA CA 92037
Fred A Middleton director, 10 percent owner 400 SOUTH EL CAMINO REAL STE 1200, SAN MATEO CA 94402-1708
Eric Bjerkholt director 132 PURDURE AVENUE, KENGSINGTON CA 94708
Sanderling Ventures Vii (canada), L.p. 10 percent owner 1300 S. EL CAMINO REAL, SUITE 203, SAN MATEO CA 94402
Sanderling Ventures Management Vi 10 percent owner 1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Sanderling Vi Beteiligungs Gmbh & Co Kg 10 percent owner 1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Sanderling Vi Limited Partnership 10 percent owner 1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Sanderling Venture Partners Vi Co Investment Fund Lp 10 percent owner 1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Sanderling Venture Partners Vi Lp 10 percent owner 1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Allan Shaw director C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
Michael J. Dunn officer: President and COO C/O CALCIMEDICA, INC., 505 COAST BOULEVARD SOUTH, LA JOLLA CA 92037
Kenneth A. Stauderman officer: Chief Scientific Officer C/O CALCIMEDICA, INC., 505 COAST BOULEVARD SOUTH, LA JOLLA CA 92037